Fig. 7.

Effect of MBX-102 acid on osteoblast/adipocyte differentiation pathways in murine C3H10T1/2 mesenchymal stem cells. A, Alkaline phosphatase activity. Rosiglitazone treatment significantly inhibited retinoic acid-stimulated alkaline phosphatase activity, whereas MBX-102 acid had no effect on this bone marker. B, Triglyceride deposition was dramatically increased by rosiglitazone treatment. MBX-102 acid had little effect on lipid accumulation and was able to fully antagonize the adipogenic capacity of rosiglitazone. Values are mean ± sem and are representative of three independent experiments (**, P < 0.01; ***, P < 0.001 vs. ATRA control; ###, P < 0.001 vs. rosiglitazone/ATRA-treated; one-way ANOVA and Tukey’s multiple comparison test).